Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 44-59

  Camilleri, M ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE; BENZAMIDE; BENZOFURAN CARBOXAMIDE; BENZOFURAN DERIVATIVE; CISAPRIDE; DIPHENOXYLATE; DIPHENYLMETHANE; GASTROINTESTINAL AGENT; INTESTINAL CHLORIDE SECRETAGOGUE; LACTULOSE; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MU OPIATE RECEPTOR ANTAGONIST; NARONAPRIDE; NORADRENALIN UPTAKE INHIBITOR; OPIATE ANTAGONIST; PERIPHERALLY RESTRICTED MU OPIOID RECEPTOR ANTAGONIST; PLECANATIDE; PRUCALOPRIDE; QUINOLINONE CARBOXAMIDE; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SORBITOL; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELUSETRAG;

CONSTIPATION; DIARRHEA; DRUG MECHANISM; FIBER; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; IRRITABLE COLON; LOWER GASTROINTESTINAL MOTILITY DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; TREATMENT OUTCOME;

EID: 84055169868     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.261     Document Type: Review

References (196)

1. Voderholzer, W.A., Schatke, W., M-ldorfer, B.E., Klauser, A.G., Birkner, B. & M-ler-Lissner, S.A. Clinical response to dietary fiber treatment of chronic constipation. Am. J. Gastroenterol. 92, 95-98 (1997). (Pubitemid 27027036)
2. Suares, N.C. & Ford, A.C. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment. Pharmacol. Ther. 33, 895-901 (2011).
3. Dipalma, J.A., Cleveland, M.V., McGowan, J. & Herrera, J.L. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am. J. Gastroenterol. 102, 1436-1441 (2007). (Pubitemid 46976282)
4. Kienzle-Horn, S., Vix, J.M., Schuijt, C., Peil, H., Jordan, C.C. & Kamm, M.A. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment. Pharmacol. Ther. 23, 1479-1488 (2006).
5. Drossman, D.A., Camilleri, M., Mayer, E.A. & Whitehead, W.E. AGA technical review on irritable bowel syndrome. Gastroenterology 123, 2108-2131 (2002). (Pubitemid 35408332)
6. Camilleri, M. & Mayer, E.A. Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes? Gastroenterology 137, 766-769 (2009).
7. Kim, D.Y. & Camilleri, M. Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. 95, 2698-2709 (2000).
8. Hoyer, D., Hannon, J.P. & Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533-554 (2002). (Pubitemid 34219205)
9. Tonini, M. & Pace, F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig. Dis. 24, 59-69 (2006).
10. Maddern, G.J., Jamieson, G.G., Myers, J.C. & Collins, P.J. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Gut 32, 470-474 (1991).
11. Tack, J., Broeckaert, D., Coulie, B. & Janssens, J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment. Pharmacol. Ther. 12, 761-766 (1998). (Pubitemid 28369883)
12. Hegde, S.S. & Eglen, R.M. Peripheral 5-HT4 receptors. FASEB J. 10, 1398-1407 (1996).
13. Prather, C.M., Camilleri, M., Zinsmeister, A.R., McKinzie, S. & Thomforde, G. Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 118, 463-468 (2000). (Pubitemid 30140843)
14. Quigley, E.M., Wald, A., Fidelholtz, J., Boivin, M., Pecher, E. & Earnest, D. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin. Gastroenterol. Hepatol. 4, 605-613 (2006).
15. Evans, B.W., Clark, W.K., Moore, D.J. & Whorwell, P.J. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst. Rev. CD003960 (2007).
16. De Maeyer, J.H., Lefebvre, R.A. & Schuurkes, J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 20, 99-112 (2008).
17. Mohammad, S., Zhou, Z., Gong, Q. & January, C.T. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. 273, H2534-H2538 (1997).
18. Camilleri, M., Beyens, G., Kerstens, R., Robinson, P. & Vandeplassche, L. Safety assessment of prucalopride in elderly patients with constipation: a doubleblind, placebo-controlled study. Neurogastroenterol. Motil. 21, 1256-e117 (2009).
19. Vazquez-Roque, M.I., Camilleri, M., Vella, A., Carlson, P., Laugen, J. & Zinsmeister, A.R. Association of TCF7L2 allelic variations with gastric function, satiation, and GLP-1 levels. Clin. Transl. Sci. 4, 183-187 (2011).
20. Nilsson, T. et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372, 49-56 (1999). (Pubitemid 29229863)
21. Maassen VanDenBrink, A., Reekers, M., Bax, W.A. & Saxena, P.R. Human isolated coronary artery contraction to sumatriptan characterised by the selective 5-HT1B/1D receptor antagonist GR55562. Pharmacol. Toxicol. 86, 287-290 (2000). (Pubitemid 30413406)
22. Villal, C.M. & Centuri, D. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch. Pharmacol. 376, 45-63 (2007).
23. Manabe, N., Wong, B.S. & Camilleri, M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin. Investig. Drugs 19, 765-775 (2010).
24. US Food and Drug Administration. Public health advisory: tegaserod maleate (marketed as Zelnorm) 〈http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051284. htm〉 (2007).
25. Beattie, D.T. et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 143, 549-560 (2004). (Pubitemid 39524272)
26. Busti, A.J., Murillo, J.R. Jr & Cryer, B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 24, 526-531 (2004). (Pubitemid 38420542)
27. Camilleri, M. & Bharucha, A.E. Behavioural and new pharmacological treatments for constipation: getting the balance right. Gut 59, 1288-1296 (2010).
28. De Maeyer, J.H., Lefebvre, R.A., & Schuurkes, J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 20, 99-112 (2008).
29. De Maeyer, J.H., Prins, N.H., Schuurkes, J.A. & Lefebvre, R.A. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J. Pharmacol. Exp. Ther. 317, 955-964 (2006). (Pubitemid 43764097)
30. Bouras, E.P., Camilleri, M., Burton, D.D., Thomforde, G., McKinzie, S. & Zinsmeister, A.R. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120, 354-360 (2001). (Pubitemid 32147632)
31. Sloots, C.E. et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment. Pharmacol. Ther. 16, 759-767 (2002). (Pubitemid 34407524)
32. Camilleri, M., Kerstens, R., Rykx, A. & Vandeplassche, L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358, 2344-2354 (2008). (Pubitemid 351749158)
33. Quigley, E.M., Vandeplassche, L., Kerstens, R. & Ausma, J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebocontrolled study. Aliment. Pharmacol. Ther. 29, 315-328 (2009).
34. Tack, J., van Outryve, M., Beyens, G., Kerstens, R. & Vandeplassche, L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58, 357-365 (2009).
35. Smith, J.A., Beattie, D.T., Marquess, D., Shaw, J.P., Vickery, R.G. & Humphrey, P.P. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol. 378, 125-137 (2008).
36. Beattie, D.T. et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol. 378, 139-147 (2008).
37. Manini, M.L. et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol. Motil. 22, 42-49, e7 (2010).
38. Goldberg, M. et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation-a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment. Pharmacol. Ther. 32, 1102-1112 (2010).
39. Dennis, D.A., Komistek, R.D., Mahfouz, M.R., Walker, S.A. & Tucker, A. A multicenter analysis of axial femorotibial rotation after total knee arthroplasty. Clin. Orthop. Relat. Res. 180-189 (2004). (Pubitemid 39506172)
40. Camilleri, M. et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol. Motil. 19, 30-38 (2007). (Pubitemid 44952776)
41. Barrett, K.E. & Keely, S.J. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu. Rev. Physiol. 62, 535-572 (2000). (Pubitemid 30618274)
42. Cuppoletti, J. et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am. J. Physiol., Cell Physiol. 287, C1173-C1183 (2004). (Pubitemid 39382875)
43. Bijvelds, M.J., Bot, A.G., Escher, J.C. & De Jonge, H.R. Activation of intestinal Cl-secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 137, 976-985 (2009).
44. Bassil, A.K. et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br. J. Pharmacol. 154, 126-135 (2008). (Pubitemid 351634400)
45. Camilleri, M. et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G942-G947 (2006).
46. Sweetser, S. et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G295-G301 (2009).
47. Cuppoletti, J., Malinowska, D.H., Chakrabarti, J. & Ueno, R. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat. 86, 56-60 (2008).
48. Johanson, J.F. & Ueno, R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment. Pharmacol. Ther. 25, 1351-1361 (2007). (Pubitemid 46763456)
49. Johanson, J.F., Morton, D., Geenen, J. & Ueno, R. Multicenter, 4-week, doubleblind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol. 103, 170-177 (2008).
50. Vaandrager, A.B. Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C. Mol. Cell. Biochem. 230, 73-83 (2002). (Pubitemid 34257243)
51. Beltowski, J. Guanylin and related peptides. J. Physiol. Pharmacol. 52, 351-375 (2001). (Pubitemid 32946277)
52. Joo, N.S., London, R.M., Kim, H.D., Forte, L.R. & Clarke, L.L. Regulation of intestinal Cl-and HCO3-secretion by uroguanylin. Am. J. Physiol. 274, G633-G644 (1998).
53. Donowitz, M. et al. NHERF family and NHE3 regulation. J. Physiol. (Lond.) 567, 3-11 (2005). (Pubitemid 41167297)
54. Andresen, V. et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133, 761-768 (2007). (Pubitemid 47374145)
55. Busby, R.W. et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649, 328-335 (2010).
56. Johnston, J.M. et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am. J. Gastroenterol. 104, 125-132 (2009).
57. Lembo, A.J. et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138, 886-895.e1 (2010).
58. Johnston, J.M. et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 139, 1877-1886.e2 (2010).
59. Shailubhai, K., Gerson, W.A., Talluto, C. & Jacob, G.S. SP-304 to treat GI disorders-effects of a single, oral-dose of SP-304 on safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Gastroenterology 136 (suppl. 1), A-641 (2009).
60. Shailubhai, K., Talluto, C., Comiskey, S., Foss, J.A., Joslyn, A., Jacob, G. Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation. Am. J. Gastroenterol. 105, S487-S488 (2010).
61. Hofmann, A.F. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159, 2647-2658 (1999).
62. Chadwick, V.S., Gaginella, T.S., Carlson, G.L., Debongnie, J.C., Phillips, S.F. & Hofmann, A.F. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J. Lab. Clin. Med. 94, 661-674 (1979). (Pubitemid 10210498)
63. Conley, D.R., Coyne, M.J., Bonorris, G.G., Chung, A. & Schoenfield, L.J. Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am. J. Dig. Dis. 21, 453-458 (1976).
64. Mekjian, H.S., Phillips, S.F. & Hofmann, A.F. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J. Clin. Invest. 50, 1569-1577 (1971).
65. Wingate, D.L., Phillips, S.F. & Hofmann, A.F. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. J. Clin. Invest. 52, 1230-1236 (1973).
66. Kirwan, W.O., Smith, A.N., Mitchell, W.D., Falconer, J.D. & Eastwood, M.A. Bile acids and colonic motility in the rabbit and the human. Gut 16, 894-902 (1975).
67. Bampton, P.A., Dinning, P.G., Kennedy, M.L., Lubowski, D.Z. & Cook, I.J. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G443-G449 (2002). (Pubitemid 34651659)
68. Odunsi, S.T. et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin. Gastroenterol. Hepatol. 8, 159-165 (2010).
69. Rao, A.S. et al. Chenodeoxycholate in females with irritable bowel syndromeconstipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139, 1549-1558, 1558.e1 (2010).
70. Bazzoli, F., Malavolti, M., Petronelli, A., Barbara, L. & Roda, E. Treatment of constipation with chenodeoxycholic acid. J. Int. Med. Res. 11, 120-123 (1983). (Pubitemid 13118507)
71. Saettone, M.F., Et, M.T. & Giannaccini, B. Inhibition of bergaptene toxicity by UV-A filters. Int. J. Cosmet. Sci. 5, 201-213 (1983). (Pubitemid 14238861)
72. Simr, M., Bajor, A., Gillberg, P.G., Rudling, M. & Abrahamsson, H. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment. Pharmacol. Ther. 34, 41-50 (2011).
73. Wong, B. Points of view: arrows. Nat. Methods 8, 701 (2011).
74. Chey, W.D., Camilleri, M., Chang, L., Rikner, L. & Graffner, H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am. J. Gastroenterol. 106, 1803-1812 (2011).
75. Morvay, K., Szentléki, K., Török, G., Pintér A., Börzsönyi, M. & Nawroth, R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats. Dis. Colon Rectum 32, 860-863 (1989). (Pubitemid 19255377)
76. Buchwald, H. et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch. Intern. Med. 158, 1253-1261 (1998). (Pubitemid 28252490)
77. Buchwald, H., Rudser, K.D., Williams, S.E., Michalek, V.N., Vagasky, J. & Connett, J.E. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann. Surg. 251, 1034-1040 (2010).
78. Bajor, A., Gillberg, P.G. & Abrahamsson, H. Bile acids: short and long term effects in the intestine. Scand. J. Gastroenterol. 45, 645-664 (2010).
79. Camilleri, M. Opioid-induced constipation: challenges and therapeutic opportunities. Am. J. Gastroenterol. 106, 835-842; quiz, 843 (2011).
80. Basilisco, G., Camboni, G., Bozzani, A., Paravicini, M. & Bianchi, P.A. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig. Dis. Sci. 32, 829-832 (1987). (Pubitemid 17135284)
81. Kaufman, P.N. et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 94, 1351-1356 (1988).
82. Meissner, W., Schmidt, U., Hartmann, M., Kath, R. & Reinhart, K. Oral naloxone reverses opioid-associated constipation. Pain 84, 105-109 (2000).
83. Vondrackova, D. et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J. Pain 9, 1144-1154 (2008).
84. Meissner, W. et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur. J. Pain 13, 56-64 (2009).
85. Sandner-Kiesling, A. et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of noncancer chronic pain. Int. J. Clin. Pract. 64, 763-774 (2010).
86. Yuan, C.S. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann. Pharmacother. 41, 984-993 (2007).
87. Y uan, C.S. et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283, 367-372 (2000).
88. Yuan, C.S., Foss, J.F., Osinski, J., Toledano, A., Roizen, M.F. & Moss, J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. 61, 467-475 (1997). (Pubitemid 27195949)
89. Yuan, C.S., Foss, J.F., O'Connor, M., Toledano, A., Roizen, M.F. & Moss, J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin. Pharmacol. Ther. 59, 469-475 (1996). (Pubitemid 26151630)
90. Yuan, C.S., Foss, J.F., O'Connor, M., Osinski, J., Roizen, M.F. & Moss, J. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 83, 631-635 (1999).
91. Yuan, C.S. et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. 67, 398-404 (2000).
92. Thomas, J. et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N. Engl. J. Med. 358, 2332-2343 (2008). (Pubitemid 351749157)
93. Wong, B.S. et al. The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment. Pharmacol. Ther. 32, 884-893 (2010).
94. Webster, L.R. et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J. Pain Symptom Manage. 40, 734-746 (2010).
95. Webster, L. et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137, 428-440 (2008).
96. Gonenne, J. et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin. Gastroenterol. Hepatol. 3, 784-791 (2005). (Pubitemid 41116731)
97. Neumann, T.A. et al. Clinical investigation of oral NKTR-118 as a selective oral peripheral opioid antagonist. Proceedings of the 18th Annual Clinical Meeting of the American Academy of Pain Management, Las Vegas, NV, 27-30 September 2007. Abstract 27.
98. Webster, L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med. 10 (suppl. 2), S124-S133 (2009).
99. Theravance. TD-1211: peripherally restricted μ opioid receptor antagonist-phase 1 and 2 results 〈http://files.shareholder.com/downloads/ THERA/1065777793x0x411486/56fc683c-c436-4a24-85 de-08622a292435/THRX-1021. pdf〉
100. DiPetrillo, L. et al. ALKS 37, a novel, peripherally-restricted opioid receptor antagonist, demonstrates efficacy in the treatment of opioid-induced bowel dysfunction. Gastroenterology 140, S405 (2011).
101. Bee, L.A., Bannister, K., Rahman, W. & Dickenson, A.H. Mu-opioid and noradrenergic a(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 152, 131-139 (2011).
102. A filalo, M. et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study. Clin. Drug Investig. 30, 489-505 (2010).
103. Buynak, R. et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled Phase III study. Expert Opin. Pharmacother. 11, 1787-1804 (2010).
104. Slappendel, R., Simpson, K., Dubois, D. & Keininger, D.L. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur. J. Pain 10, 209-217 (2006). (Pubitemid 43255207)
105. Sloots, C.E., Rykx, A., Cools, M., Kerstens, R. & De Pauw, M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig. Dis. Sci. 55, 2912-2921 (2010).
106. Bearcroft, C.P., Perrett, D. & Farthing, M.J. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42, 42-46 (1998). (Pubitemid 28228386)
107. Dunlop, S.P. et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 3, 349-357 (2005). (Pubitemid 40488343)
108. A tkinson, W., Lockhart, S., Whorwell, P.J., Keevil, B. & Houghton, L.A. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrheapredominant irritable bowel syndrome. Gastroenterology 130, 34-43 (2006). (Pubitemid 43049833)
109. Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine. Ann. Intern. Med. 73, 607-630 (1970).
110. Shopsin, B., Friedman, E. & Gershon, S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch. Gen. Psychiatry 33, 811-819 (1976).
111. Ruh-H.G., Mason, N.S. & Schene, A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12, 331-359 (2007). (Pubitemid 46496835)
112. Redmond, D.E. Jr, Maas, J.W., Kling, A., Graham, C.W. & Dekirmenjian, H. Social behavior of monkeys selectively depleted of monoamines. Science 174, 428-431 (1971).
113. Shi, Z.C. et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J. Med. Chem. 51, 3684-3687 (2008).
114. Jin, H. et al. Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2- aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg. Med. Chem. Lett. 19, 5229-5232 (2009).
115. Roberts, B.W., Jackson, J.J., Berger, J.M., Burger, J. & Trautwein, U. Conscientiousness and externalizing psychopathology: overlap, developmental patterns, and etiology of two related constructs. Dev. Psychopathol. 21, 871-888 (2009).
116. Brown, P. Britain dithers over gene therapy. New Sci. 136, 4 (1992).
117. Zambrowicz, B. et al. 5-HT biomarker levels correlate with clinical response in phase 2 trial of LX1031, a novel 5-HT synthesis inhibitor for non-constipating IBS. Gastroenterology 136 (suppl. 1), S168 (2009).
118. Hirata, T., Funatsu, T., Keto, Y., Nakata, M. & Sasamata, M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 15, 5-9 (2007). (Pubitemid 46333875)
119. Hirata, T. et al. Effects of serotonin 5-HT3 receptor antagonists on stressinduced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol. Motil. 20, 557-565 (2008). (Pubitemid 351548641)
120. Matsueda, K., Harasawa, S., Hongo, M., Hiwatashi, N. & Sasaki, D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 77, 225-235 (2008).
121. Matsueda, K., Harasawa, S., Hongo, M., Hiwatashi, N. & Sasaki, D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand. J. Gastroenterol. 43, 1202-1211 (2008).
122. Owada, A., Nakao, M., Koike, J., Ujiie, K., Tomita, K. & Shiigai, T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int. Suppl. 63 (suppl.), S188-S190 (1997). (Pubitemid 28020467)
123. Fukuda, Y. et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, doubleblind, placebo-controlled trial. Am. J. Gastroenterol. 103, 1721-1729 (2008).
124. A nderson K. & Fischer L. Prevention of GI absorption of bacterial toxins: an in vitro evaluation of the potential for prophylactic use of a novel oral adsorbent (ast-120). Gastroenterology 134 (4 suppl. 1), A-675 (2008).
125. A nderson, K., Tomiyama, S., Nitta, T. A novel, engineered carbon microsphere product for use in chronic inflammatory bowel disease and liver dysfunction. Gastroenterology 134 (4 suppl. 1), A-675 (2008).
126. Tack, J.F., Harris, M.S., Proksch, S., Bornstein, J.D., Miner, P.B. AST-120 (spherical carbon adsorbent) improves pain and bloating in a randomized, doubleblind, placebo-controlled trial in patients with non-constipating irritable bowel syndrome (IBS). Gastroenterology 138 (5 s uppl. 1), S-223 (2010).
127. Steed, K.P., Bohemen, E.K., Lamont, G.M., Evans, D.F., Wilson, C.G. & Spiller, R.C. Proximal colonic response and gastrointestinal transit after high and low fat meals. Dig. Dis. Sci. 38, 1793-1800 (1993). (Pubitemid 23311929)
128. Deiteren, A., Camilleri, M., Burton, D., McKinzie, S., Rao, A. & Zinsmeister, A.R. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig. Dis. Sci. 55, 384-391 (2010).
129. Marciani, L. et al. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 138, 469-477, 477.e1 (2010).
130. Ragnarsson, G. & Bodemar, G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur. J. Gastroenterol. Hepatol. 10, 415-421 (1998). (Pubitemid 28241429)
131. Lembo, A.J., Olden, K.W., Ameen, V.Z., Gordon, S.L., Heath, A.T. & Carter, E.G. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin. Gastroenterol. Hepatol. 2, 675-682 (2004). (Pubitemid 39013427)
132. Chey, W.D. et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 99, 2195-2203 (2004). (Pubitemid 39524711)
133. Julia, V., Su, X., Bu?o, L. & Gebhart, G.F. Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies. Gastroenterology 116, 1124-1131 (1999). (Pubitemid 29203022)
134. Greenwood-Van Meerveld, B., Gibson, M.S., Johnson, A.C., Venkova, K. & Sutkowski-Markmann, D. NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol. Biochem. Behav. 74, 1005-1013 (2003). (Pubitemid 36351664)
135. Chien, C.T., Yu, H.J., Lin, T.B., Lai, M.K. & Hsu, S.M. Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am. J. Physiol. Renal Physiol. 284, F840-F851 (2003).
136. Holzer, P. & Holzer-Petsche, U. Tachykinin receptors in the gut: physiological and pathological implications. Curr. Opin. Pharmacol. 1, 583-590 (2001). (Pubitemid 33585999)
137. Holzer, P. & Holzer-Petsche, U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol. Ther. 73, 173-217 (1997). (Pubitemid 27224437)
138. Maggi, C.A. The troubled story of tachykinins and neurokinins. Trends Pharmacol. Sci. 21, 173-175 (2000). (Pubitemid 30243198)
139. Moriarty, D., Selve, N., Baird, A.W. & Goldhill, J. Potent NK1 antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation. Am. J. Physiol., Cell Physiol. 280, C852-C858 (2001).
140. Onori, L., Aggio, A., Taddei, G. & Tonini, M. Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G137-G147 (2000). (Pubitemid 30108078)
141. Warr, D. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy. Expert Opin. Pharmacother. 7, 1653-1658 (2006). (Pubitemid 44209608)
142. Diemunsch, P., Joshi, G.P. & Brichant, J.F. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br. J. Anaesth. 103, 7-13 (2009).
143. Grunberg, S.M. et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 549-558 (2009).
144. Oh-Young, L., Manakata, J. & Naliboff, B. A double-blind, parallel group pilot study of the effects of CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 118, A846 (2000).
145. Houghton, L.A. et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol. Motil. 19, 732-743 (2007). (Pubitemid 47312398)
146. Dukes, G.E. et al. Lack of effect of the NH3 receptor antagonist, talnetant SB223412, on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose-ranging trials. Gastroenterology 132, A60 (2007).
147. L?dal, M., Navalesi, G., Theodorsson, E., Maggi, C.A. & Hellstr?, P.M. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br. J. Pharmacol. 134, 215-223 (2001). (Pubitemid 32835485)
148. Tough, I.R., Lewis, C.A., Fozard, J. & Cox, H.M. Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa. Naunyn Schmiedebergs Arch. Pharmacol. 367, 104-108 (2003). (Pubitemid 36286868)
149. Zakko, S., Barton, G., Weber, E., Dunger-Baldauf, C. & R-l, A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 33, 1311-1321 (2011).
150. Fukudo, S., Nomura, T. & Hongo, M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42, 845-849 (1998). (Pubitemid 28277227)
151. Sagami, Y. et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53, 958-964 (2004). (Pubitemid 38824152)
152. Wallon, C. & S?erholm, J.D. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann. NY Acad. Sci. 1165, 206-210 (2009).
153. Wallon, C. et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 57, 50-58 (2008).
154. Tayama, J., Sagami, Y., Shimada, Y., Hongo, M. & Fukudo, S. Effect of alphahelical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 19, 471-483 (2007). (Pubitemid 46905393)
155. Sweetser, S. et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1299-G1306 (2009).
156. Thoua, N.M. et al. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 29, 552-560 (2009).
157. Jarcho, J.M., Mayer, E.A. & London, E.D. Neuroimaging placebo effects: new tools generate new questions. Clin. Pharmacol. Ther. 86, 352-354 (2009).
158. Cellek, S. et al. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology 133, 175-183 (2007). (Pubitemid 47031143)
159. Grudell, A.B. et al. Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1114-G1119 (2008).
160. Kelleher, D.L., Hicks, K.J., Cox, D.S., Williamson, R.R., Alpers, D.H. & Dukes, G.E. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 20 (suppl. 1), 131-132 (2008).
161. Pimentel, M. et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 364, 22-32 (2011).
162. Dunlop, S.P., Jenkins, D. & Spiller, R.C. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol. 98, 1578-1583 (2003). (Pubitemid 36875351)
163. O'Mahony, L. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551 (2005). (Pubitemid 40585355)
164. Lobo, B.L., Vaidean, G., Broyles, J., Reaves, A.B. & Shorr, R.I. Risk of venous thromboembolism in hospitalized patients with peripherally inserted central catheters. J. Hosp. Med. 4, 417-422 (2009).
165. Leri, O. et al. Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammopharmacology 5, 153-158 (1997). (Pubitemid 27288514)
166. Klooker, T.K. et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59, 1213-1221 (2010).
167. Corinaldesi, R. et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment. Pharmacol. Ther. 30, 245-252 (2009).
168. A ndrews, C.N., Griffiths, T.A., Kaufman, J., Vergnolle, N., Surette, M.G. & Rioux, K.P. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea- predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 34, 374-383 (2011).
169. Dunlop, S.P. et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther. 18, 77-84 (2003). (Pubitemid 36897983)
170. Leventer, S.M. et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am. J. Gastroenterol. 99 (10 suppl. 5), S279 (2004).
171. Leventer, S.M. et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment. Pharmacol. Ther. 27, 197-206 (2008). (Pubitemid 350256611)
172. Grover, M., Dorn, S.D., Weinland, S.R., Dalton, C.B., Gaynes, B.N. & Drossman, D.A. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig. Dis. Sci. 54, 1284-1291 (2009).
173. Delvaux, M., Louvel, D., Lagier, E., Scherrer, B., Abitbol, J.L. & Frexinos, J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116, 38-45 (1999). (Pubitemid 29013491)
174. Delgado-Aros, S. et al. Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am. J. Physiol. 284, 558-566 (2003).
175. Mangel, A.W. et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 28, 239-249 (2008). (Pubitemid 351861967)
176. Szarka, L.A. et al. Efficacy of on-demand asimadoline, a peripheral κ-opioid agonist, in females with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 5, 1268-1275 (2007). (Pubitemid 350019057)
177. Hellstr?, P.M. et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol. Motil. 20, 649-659 (2008).
178. Hellstr, P.M., Hein, J., Bytzer, P., Bjnss, E., Kristensen, J. & Schambye, H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebocontrolled, double-blind study. Aliment. Pharmacol. Ther. 29, 198-206 (2009).
179. Petrenko, A.B., Yamakura, T., Baba, H. & Shimoji, K. The role of N-methyl-Daspartate (NMDA) receptors in pain: a review. Anesth. Analg. 97, 1108-1116 (2003). (Pubitemid 37158698)
180. Siu, A. & Drachtman, R. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev. 13, 96-106 (2007). (Pubitemid 46697843)
181. Zhou, Q., Zhang, B. & Verne, G.N. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 146, 41-46 (2009).
182. Zhou, Q., Price, D.D., Callam, C.S., Woodruff, M.A. & Verne, G.N. Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome. J. Pain 12, 297-303 (2011).
183. Wolf, M., Eberhart, A., Glossmann, H., Striessnig, J. & Grigorieff, N. Visualization of the domain structure of an L-type Ca2+ channel using electron cryo-microscopy. J. Mol. Biol. 332, 171-182 (2003). (Pubitemid 36999739)
184. Field, M.J. et al. Identification of the alpha2-delta-1 subunit of voltagedependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. USA 103, 17537-17542 (2006). (Pubitemid 44789004)
185. Ben-Menachem, E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 (suppl. 6), 13-18 (2004). (Pubitemid 39350325)
186. Camilleri, M. alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome? Gut 56, 1337-1338 (2007). (Pubitemid 47517819)
187. Needham, K. et al. Identification of subunits of voltage-gated calcium channels and actions of pregabalin on intrinsic primary afferent neurons in the guinea-pig ileum. Neurogastroenterol. Motil. 22, e301-e308 (2010).
188. Diop, L., Raymond, F., Fargeau, H., Petoux, F., Chovet, M. & Doherty, A.M. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J. Pharmacol. Exp. Ther. 302, 1013-1022 (2002). (Pubitemid 34920221)
189. Million, M., Wang, L., Adelson, D.W., Roman, F., Diop, L. & Tach-Y. Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats. Gut 56, 1482-1484 (2007). (Pubitemid 47517859)
190. Moore, R.A., Straube, S., Wiffen, P.J., Derry, S. & McQuay, H.J. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst. Rev. CD007076 (2009).
191. Ravnefjord, A., Brusberg, M., Larsson, H., Lindstr?, E. & Mart?ez, V. Effects of pregabalin on visceral pain responses and colonic compliance in rats. Br. J. Pharmacol. 155, 407-416 (2008).
192. Houghton, L.A., Fell, C., Whorwell, P.J., Jones, I., Sudworth, D.P. & Gale, J.D. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56, 1218-1225 (2007). (Pubitemid 47300421)
193. Iturrino, J., Camilleri, M., Busciglio, I., Burton, D. & Zinsmeister, A.R. Effect of the a2d ligand, pregabalin, on colonic sensory and motor functions in healthy adults. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G377-G384 (2011).
194. Manabe, N., Rao, A.S., Wong, B.S. & Camilleri, M. Emerging pharmacologic therapies for irritable bowel syndrome. Curr. Gastroenterol. Rep. 12, 408-416 (2010).
195. Camilleri, M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol. Motil. 17, 311-316 (2005).
196. Camilleri, M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment. Pharmacol. Ther. 31, 35-46 (2010).